Amanda B. Robinson

Clients rely on Amanda for a host of white collar matters, including criminal product liability and consumer protection issues, financial fraud investigations arising under the False Claims Act (FCA), Foreign Corrupt Practices Act (FCPA), and federal antitrust laws, as well as matters involving national security. Amanda’s work crosses multiple industries with a particular focus in the technology and life sciences areas. Amanda also manages large parallel litigation teams in actions, including multi-district litigation (MDL), arising from the same government investigations and complex disputes.

Amanda also counsels members of US Congress, executive branch officials, and executive branch nominees regarding compliance with ethics laws and rules, including public financial disclosure statements and other disclosure obligations.

Prior to joining Morgan Lewis, Amanda was counsel and presidential management fellow with the Office of Inspector General (OIG) for the US Department of Health and Human Services (HHS). In that capacity, she issued advisory opinions on fraud and abuse issues associated with Medicare and Medicaid, including the federal Stark and antikickback laws, OIG exclusion authorities, and civil money penalties.

Earlier in her career, Amanda worked at the White House, where she provided direct support to US President George W. Bush. In addition to traveling with the president, she coordinated the flow of official documents, helped draft executive orders and briefing papers, and managed the speechwriting process.

Amanda received her J.D. from the College of William & Mary, Marshall-Wythe School of Law, where she served as the symposium editor of the William and Mary Bill of Rights Journal. She also served as a law clerk for the US House of Representatives Committee on Ways and Means and the US Senate Committee on the Judiciary, and as a judicial extern for Judge Richard Leon on the US District Court for the District of Columbia.

Litigation and Enforcement Matters

• Representation of global pharmaceutical company in non-intervened qui tam litigations involving allegations of off-label promotion of pharmaceutical products
• Representation of technology company before the Federal Acquisition Security Council (FASC) in a federal exclusion and removal matter relating to supply chain risk
• Representation of technology company in connection with a US Department of Commerce investigation involving the company’s information and communications technology and services (ICTS)
• Successful representation of large retail pharmacy in two FCA investigations involving allegations relating to dispensing and billing practices
• Representation of US corporate parent in internal investigation of potential trade sanctions violations by its European and Middle Eastern subsidiaries
• Management of a cross-border investigation of alleged corruption by vendors of a major US manufacturer, including interviews across Europe and Russia and enforcement inquiries from US and European law enforcement agencies
• Representation of large financial institution in connection with a Consumer Financial Protection Bureau (CFPB) investigation relating to sales practices
• Counsel for high-profile Cabinet Secretary regarding an OIG investigation
• Representation of international humanitarian response organization in a United States Agency for International Development (USAID) OIG investigation
• Representation of large technology company in confidential DOJ investigation in connection with standards-setting activities
• Management of federal multidistrict litigation (MDL) In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation
• Defending leading generic pharmaceutical manufacturer in MDL regarding alleged price fixing and market allocation
• Representation of leading generic pharmaceutical manufacturer in criminal and civil antitrust investigations
• Representation of pharmacies and pharmacy owners and employees in FCA investigations

Congressional Representations

• Successfully defended a US Congressman in an Office of Congressional Ethics investigation, obtaining a unanimous recommendation to dismiss complaint
• Counsel for a professional grantmaking charitable organization in an investigation regarding Chinese influence in American energy and environmental policy by the House Committee on Energy and Commerce; House Committee on Science, Space, and Technology; and House Committee on Natural Resources
• Counsel to financial institutions in connection with House Judiciary Committee investigation examining potential collusion to promote ESG-related goals in the investment industry, including through Climate Action 100+
• Counsel for financial institution in connection with investigation by House Committee on Oversight and Reform
• Counsel for large pharmaceutical distributor in connection with an opioid-related investigation by the House Committee on Energy & Commerce and prepared CEO to testify at oversight hearing
• Counsel for large freight carrier in connection with inquiry by Senate Committee on Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations (PSI)